24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation

New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxacin or clofazimine, could improve treatment efficacy, safety, and tolerability, and free up resources within the health system. Following a change to WHO...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet global health Vol. 13; no. 2; pp. e355 - e363
Main Authors:	Sweeney, Sedona, Laurence, Yoko V, Berry, Catherine, Singh, Maninder Pal, Dodd, Matthew, Fielding, Katherine, Kazounis, Emil, Moodliar, Ronelle, Solodovnikova, Varvara, Tigay, Zinaida, Liverko, Irina, Parpieva, Nargiza, Butabekov, Ilhomjon, Usmanova, Ruzilya, Rassool, Mohammed, Motta, Ilaria, Nyangweso, George Mokua, Jolivet, Pascal, Abdrasuliev, Tleubergen, Moe, Soe, Aw, Pei Sun, Samieva, Nazgul, Nyang'wa, Bern-Thomas
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.02.2025
Subjects:	Administration, Oral Adult Antitubercular Agents - administration & dosage Antitubercular Agents - economics Antitubercular Agents - therapeutic use Cost-Benefit Analysis Diarylquinolines - economics Diarylquinolines - therapeutic use Drug Therapy, Combination Female Humans Male Quality-Adjusted Life Years Rifampin - therapeutic use South Africa Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - economics Tuberculosis, Pulmonary - drug therapy South Africa
ISSN:	2214-109X, 2214-109X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!